239 related articles for article (PubMed ID: 30811755)
1. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women.
Park C; Yoon KA; Kim J; Park IH; Park SJ; Kim MK; Jang W; Cho SY; Park B; Kong SY; Lee ES
Cancer Sci; 2019 May; 110(5):1760-1770. PubMed ID: 30811755
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
3. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic and transcriptomic analysis for pinpointing recurrent alterations of plant homeodomain genes and their clinical significance in breast cancer.
Yu H; Jiang Y; Liu L; Shan W; Chu X; Yang Z; Yang ZQ
Oncotarget; 2017 Feb; 8(8):13099-13115. PubMed ID: 28055972
[TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
8. Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer.
Wang Y; Gong X; Zhang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34406386
[TBL] [Abstract][Full Text] [Related]
9. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.
Aure MR; Vitelli V; Jernström S; Kumar S; Krohn M; Due EU; Haukaas TH; Leivonen SK; Vollan HK; Lüders T; Rødland E; Vaske CJ; Zhao W; Møller EK; Nord S; Giskeødegård GF; Bathen TF; Caldas C; Tramm T; Alsner J; Overgaard J; Geisler J; Bukholm IR; Naume B; Schlichting E; Sauer T; Mills GB; Kåresen R; Mælandsmo GM; Lingjærde OC; Frigessi A; Kristensen VN; Børresen-Dale AL; Sahlberg KK;
Breast Cancer Res; 2017 Mar; 19(1):44. PubMed ID: 28356166
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
12. Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling.
Cornen S; Guille A; Adélaïde J; Addou-Klouche L; Finetti P; Saade MR; Manai M; Carbuccia N; Bekhouche I; Letessier A; Raynaud S; Charafe-Jauffret E; Jacquemier J; Spicuglia S; de The H; Viens P; Bertucci F; Birnbaum D; Chaffanet M
PLoS One; 2014; 9(1):e81843. PubMed ID: 24416132
[TBL] [Abstract][Full Text] [Related]
13. Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
[TBL] [Abstract][Full Text] [Related]
14. How Young Is Too Young in Breast Cancer?-Young Breast Cancer Is Not a Unique Biological Subtype.
Fu J; Wu L; Fu W; Tan Y; Xu T; Hong Z; Wang F; Li S
Clin Breast Cancer; 2018 Feb; 18(1):e25-e39. PubMed ID: 28802528
[TBL] [Abstract][Full Text] [Related]
15. BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.
Hwang KT; Kim K; Chang JH; Oh S; Kim YA; Lee JY; Jung SH; Choi IS
Cancer Res Treat; 2018 Jul; 50(3):658-669. PubMed ID: 28701032
[TBL] [Abstract][Full Text] [Related]
16. Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.
Xiao B; Hang J; Lei T; He Y; Kuang Z; Wang L; Chen L; He J; Zhang W; Liao Y; Sun Z; Li L
Mol Biol Rep; 2019 Apr; 46(2):2111-2119. PubMed ID: 30888555
[TBL] [Abstract][Full Text] [Related]
17. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing.
Chen P; Song W; Liu L
Gynecol Obstet Invest; 2018; 83(4):338-348. PubMed ID: 29241203
[TBL] [Abstract][Full Text] [Related]
20. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]